Melanoma is one of the leading causes of skin cancer deaths, accounting for 48,000 fatalities worldwide each year. It is one of the more rare types of skin cancer but causes the majority of skin cancer related deaths. This collaboration seeks to identify microRNAs that can be used as prognostic indicators for the overall survival of melanoma patients and the risk that the disease will metastasize to distant sites.
"Each year more than 150,000 people are diagnosed with melanoma," said Dr. Eva Hernando of the Department of Pathology at the NYU School of Medicine. "We believe that through our work with microRNAs, which have been shown to hold tremendous potential as biomarkers, we will be able to better understand both the origins and the development of the disease. NYU's extensive experience with melanoma, combined with Rosetta Genomics unmatched knowledge in microRNAs offers an exciting research opportunity."
"We see microRNAs as the biomarkers of the future," said Dr. Dalia Cohen, Executive Vice President, Global Research and Development of Rosetta Genomics. "There is a large and growing body of scientific evidence pointing to microRNAs' potential as diagnostic and prognostic biomarkers for various types of cancers. We believe our work with world renowned experts in melanoma such as Dr. Nina Bhardwaj at NYU, and deploying the proprietary tools developed at Rosetta Genomics for microRNA extraction, identification and quantification, will help to more fully understand melanoma and subsequently the prognosis of melanoma patients."
MicroRNAs (miRNAs) are a recently discovered, naturally occurring form
of RNAi. These small RNAs act as protein regulators and have the potential
to form the basis for a new class of diagnostics and therapeutics. Since
many diseases are caused by the abnormal
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved